Candel TherapeuticsNASDAQ: CADL

Candel Therapeutics Inc (NASDAQ:CADL) recently presented insights into its oncolytic virus therapy, CAN-3110, at the Society for Immunotherapy of Cancer (SITC) conference. The company's Chief Scientific Officer, Dr.

NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-3110, a next generation oncolytic viral immunotherapy, for the treatment of recurrent high-grade glioma (rHGG). Glioblastoma (GBM) is the most common and aggressive form of high-grade glioma.

Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.

Candel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy.

Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC

Candel Therapeutics, Inc. announced encouraging interim findings from the phase 2 trial of CAN-2409 in treating pancreatic ductal adenocarcinoma, showing a median overall survival of 28.8 months when used in combination with standard of care. The FDA has granted Orphan Drug Designation for CAN-2409 in borderline resectable pancreatic ductal adenocarcinoma. Results from the phase 2 study evaluating CAN-2409 in non-small cell lung cancer are anticipated in the second quarter of 2024.

Candel (CADL) surges 43% after the FDA awards orphan drug status to its main candidate, CAN-2409, for the treatment of non-metastatic pancreatic cancer.

Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.